SPRY vs. RVMD, LEGN, GRFS, TGTX, LNTH, NUVL, TLX, AXSM, ADMA, and AKRO
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.
ARS Pharmaceuticals vs. Its Competitors
ARS Pharmaceuticals (NASDAQ:SPRY) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.
ARS Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.
ARS Pharmaceuticals currently has a consensus target price of $31.00, suggesting a potential upside of 82.89%. Revolution Medicines has a consensus target price of $68.00, suggesting a potential upside of 86.61%. Given Revolution Medicines' higher probable upside, analysts clearly believe Revolution Medicines is more favorable than ARS Pharmaceuticals.
ARS Pharmaceuticals has higher revenue and earnings than Revolution Medicines. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Revolution Medicines has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -16.11%. ARS Pharmaceuticals' return on equity of -6.94% beat Revolution Medicines' return on equity.
68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 33.5% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Revolution Medicines had 3 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 9 mentions for Revolution Medicines and 6 mentions for ARS Pharmaceuticals. Revolution Medicines' average media sentiment score of 1.07 beat ARS Pharmaceuticals' score of 0.83 indicating that Revolution Medicines is being referred to more favorably in the news media.
Summary
Revolution Medicines beats ARS Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ARS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SPRY) was last updated on 7/9/2025 by MarketBeat.com Staff